Long-term outcomes of endoscopic procedures for upper gastrointestinal cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect data on patients undergoing Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR), or Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions. It will assess lesion characteristics, procedural outcomes, safety, and efficacy of these interventions. The study will focus on lesions larger than 10mm and will gather prospective data to evaluate long-term outcomes. The findings could provide valuable insights into the effectiveness of these endoscopic techniques in treating upper GI cancers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* UGI neoplastic lesions \> 10mm

  * Lesions for ESD limited to the mucosal and/or submucosal layer OR
  * Lesions for EFTR limited to the muscularis propria layer OR
  * Lesions for STER limited to the submucosal and/or muscularis propria layer
* Aged 18 years or older

Exclusion Criteria:

* Age less than 18
* Unable to give informed consent
* Pregnant or lactating patients
* Patients with bleeding diathesis or who cannot discontinue ADP blockers (e.g. clopidogrel, prasugrel) or antithrombotics (e.g. warfarin, dabigatran) periprocedurally

Where it's running

• Westmead Hospital
  Sydney, New South Wales, Australia Recruiting

Study contacts

• Principal investigator: Michael Bourke — Wslhd
• Study coordinator: Michael Bourke
• Email: michael@citywestgastro.com.au
• Phone: 02 8890 5555

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Total neoadjuvant chemotherapy for advanced gastric and gastroesophageal cancer

  This study is testing two different chemotherapy plans for people with advanced stomach cancer to see which one helps them better tolerate treatment and successfully have surgery.

  Recruiting at 2 sites Phase 2/3 Ukrainian Society of Clinical Oncology · Vilnius and 1 other locations · NCT06028737

• Olanzapine added to chemotherapy for gastric cancer to help keep weight and appetite up

  This study tests whether adding low-dose olanzapine to standard neoadjuvant chemotherapy helps patients with gastric cancer maintain weight and appetite during treatment.

  Recruiting Phase 2 University of Illinois Chicago · Chicago, Illinois · NCT07581405

• BHB810 in advanced gastric and GEJ cancer (early-phase)

  This study tests whether BHB810 can be safely given every two weeks to adults with advanced gastric or GEJ adenocarcinoma and looks at its effect, how the drug behaves in the body, and patient responses.

  Recruiting at 2 sites Phase 1/2 BigHat Biosciences, Inc. · Duarte, California and 2 other locations · NCT07529808

• Direct injection of a modified vaccinia virus (vvDD-hIL2) into abdominal and gastrointestinal tumors

  This trial will try a single direct injection of a modified vaccinia virus (vvDD-hIL2) into abdominal tumors to see if it is safe for adults with advanced metastatic gastrointestinal or peritoneal cancers who have not responded to standard treatments.

  Recruiting Phase 1 Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · Pittsburgh, Pennsylvania · NCT07001592

• Using a new imaging technique to detect cancer-associated fibroblasts in various cancers

  This study is testing a new imaging method to see if it can better detect certain cancer-related cells in people with newly diagnosed esophageal or pancreatic cancer compared to standard imaging techniques.

  Recruiting at 2 sites Phase 2/3 KU Leuven · Edegem and 2 other locations · NCT06782412

• Assessing lymph node removal quality during minimally invasive gastric cancer surgery

  This study is testing a new scoring system to see if it can help doctors better assess lymph node removal during minimally invasive surgery for stomach cancer and improve patient outcomes.

  Recruiting at 7 sites Azienda Ospedaliero-Universitaria di Parma · Cremona, CR and 7 other locations · NCT06466902

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.